Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Organogenesis Holdings (ORGO) Research & Development (2017 - 2026)

Organogenesis Holdings has reported Research & Development over the past 9 years, most recently at $10.3 million for Q4 2025.

  • For Q4 2025, Research & Development fell 10.79% year-over-year to $10.3 million; the TTM value through Dec 2025 reached $44.5 million, down 11.4%, while the annual FY2025 figure was $44.5 million, 11.4% down from the prior year.
  • Research & Development for Q4 2025 was $10.3 million at Organogenesis Holdings, down from $13.2 million in the prior quarter.
  • Over five years, Research & Development peaked at $15.6 million in Q2 2024 and troughed at $6.2 million in Q1 2021.
  • A 5-year average of $10.5 million and a median of $10.4 million in 2023 define the central range for Research & Development.
  • Biggest five-year swings in Research & Development: surged 141.39% in 2021 and later tumbled 33.31% in 2025.
  • Year by year, Research & Development stood at $8.3 million in 2021, then surged by 37.95% to $11.4 million in 2022, then increased by 3.29% to $11.8 million in 2023, then decreased by 2.04% to $11.5 million in 2024, then decreased by 10.79% to $10.3 million in 2025.
  • Business Quant data shows Research & Development for ORGO at $10.3 million in Q4 2025, $13.2 million in Q3 2025, and $10.4 million in Q2 2025.